MicroRNA-1 (miR-1) stands out as the most prominent microRNA (miRNA) in regulating cardiac function and has been perceived as a new potential therapeutic target.
| INTRODUCTION
Heart failure (HF) is a common, disabling and potentially deadly condition and remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures, despite several therapeutic approaches have reduced cardiovascular morbidity and mortality. 1, 2 Therefore, to explore the pathogenesis of such disease and look for novel effective drugs with low side-effects would have great impacts on its prevention and clinical management of HF. Recently, constituents from natural herbs have attracted attention with regard to pharmaceutical development.
MicroRNA (miRNA), a small non-coding RNA, is emerged as a critical node in post-transcriptional regulation and a newly discovered class of gene regulatory factors at the core of human physiology and disease. 3, 4 Increasing lines of evidence have been rapidly evolving for function and progression of HF. 4, 5 And notably microRNA-1 (miR-1), a cardiac-enriched miRNA, is in most close relation to heart conditions, and the changes in its expression have been discovered in a variety of heart diseases. [6] [7] [8] [9] [10] Our previous report revealed that outcomes of miR-1 overexpression induced adverse structural remodelling, which impaired cardiac contractile and diastolic function and even caused HF. 11 MiR-1 could result in an epigenetic defect as cardiac hypertrophy by microinjecting fragments of miR-1. 12 The functional significance of the findings uncovered that miR-1 might be a trigger and sustainer for the structural remodelling and dysfunction of HF. Down-regulation of miR-1 may produce cardioprotective effects 7, 8, 13 and miR-1 has been perceived as a new therapeutic target for heart diseases. Therefore, it is valuable to develop new candidates regulating miR-1 by which to treat relevant heart diseases.
Lycium barbarum polysaccharides (LBPs) are important active constituents extracted from the traditional Chinese herb L. barbarum. There are scientific proofs of its pharmacological and biological functions including anti-oxidative properties, 14 immunomodulation, 15 antitumor activity, 16 anti-ageing effect, 17 neuroprotection, 18 hypoglycaemic and hypolipidemic effects 19 and male fertility-facilitating, 20 indicating extensive application prospects on relevant diseases. To the best of our knowledge, there are only a few studies concerning the effect of LBPs on cardiovascular system. Electrocardiographic and biochemical evidence were found that LBPs elicit a typical cardioprotective effect against Doxorubicin-related oxidative stress in rats and dogs. 21, 22 LBPs reduced myocardial apoptosis and injury in ischemia/reperfusion process of rat heart and could prevent the development of cardiovascular diseases. 23, 24 However, until now, no available information has addressed the effects of LBPs on cardiac structure and function in HF. Given its biological property, it is conceivable that LBPs may produce beneficial actions in preventing the development of HF and act as a potential therapy option. This study was aimed to investigate the effects of LBPs on impaired cardiac function and structural remodelling induced by overexpression of miR-1 and to unravel the underlying molecular mechanism for exploiting therapeutic potential on HF.
| MATERIALS AND METHODS

| Preparation of Lycium barbarum polysaccharides
Lycium barbarum polysaccharides were prepared using the extraction procedure optimized by Jingcheng Tang. 25 Briefly, the dry fruits of L. barbarum (0.5 kg, purchased from Xi'an Tianyuan Biologics Plant, China) were immersed in deionized water for 12 hours, boiled for . We generated Tg mouse line for cardiac-specific overexpression of miR-1 driven by the a-myosin heavy chain (a-MHC) promoter as previously reported. 11 Briefly, sexually immature female C57BL/6 mice (4-5 weeks of age) were applied to obtain sufficient quantity of eggs (>250) for microinjection. The mice used in this study were the fifth generation or later. 
| Administration of LBPs to mice
| Administration of LBPs to NRVCs
NRVCs (2 9 10 5 /well) were incubated with 2 mL fresh FBS-free medium in six-well plates and administered incremental dose of LBPs (100, 400 and 800 lg/mL). Haematoxylin and eosin (H&E) staining was performed by routine method. Hearts were taken and fixed in zinc formalin for 24-48 hours then processed using a Sakura Tissue Tek VIP5 processor.
| Evaluation of morphological remodelling
Samples were embedded in paraffin and sectioned longitudinally from the identical plane of the initial portion of the ascending aorta at 4 lm using a microtome. Sections were stained with haematoxylin and eosin for identification. Heart-to-bodyweight ratio (HW/BW) was calculated for each group. The length of sarcomeres was evaluated by Image-Pro Plus 6.0 (Media Cybernetics, Bethesda, MA).
| Quantification of miR-1 levels in Tg mice or NRVCs
The total RNA samples were isolated using Trizol and phenol/chloroform extraction procedures. MiR-1 level was quantified by the 
| Western blot analysis
The left ventricles of mice or cultured NRVCs were homogenized in lysis buffer (RIPA buffer 60%, SDS 40% and protease inhibitor cocktail 1%) on ice and then centrifuged at 18 000 g at 4°C for 30 minutes to remove the insoluble pellet. Protein concentration in the supernatant was deter- 
| Data analysis
Data were calculated as mean AE SEM (standard error of the means) except the length of sarcomeres as mean AE SD (standard deviation).
The ANOVA test was performed for statistical comparisons among multiple groups. Differences were considered statistically significant at P < .05. SPSS13.0 was used for all statistical analyses.
| RESULTS
| LBPs reduced the expression of myocardial miR-1 in vitro and in vivo
We quantified the miR-1 levels in neonatal rat ventricular cardiomyocytes (NRVCs) with incremental doses of LBPs. Excitingly, our data from qRT-PCR showed that LBPs significantly reduced the expression of endogenic miR-1 ( Figure 1A) . Similar results were observed in the overexpression model of miR-1 by transfecting miRNA mimics in NRVCs ( Figure 1B (Figure 2A,B) . TEM examination found that intercalated discs were dissolved markedly with vacuolar degeneration of gap junctions and decreased density of the macula adherents in the hearts of Tg mice but not in those treated with LBPs ( Figure 2C,D) . Figure 2D presented the quantitative analysis of percentage of damaged length in intercalated disc organization. Figure 3A ). In addition, the impaired cardiac contractile and diastolic functions of Tg mice were indicated by decreased CO, ESP, dP/dt max and dP/dt min , as well as increased EDP, ESV and EDV ( Figure 3B-H) . Interestingly, in the treatment of LBPs, the indexes of cardiac contractile function including CO, ESP, ESV and dp/dt max were seen significant restorations.
However, except EDV, the indexes of cardiac diastolic function including EDP and dP/dt min were not improved significantly in mice treated with LBPs ( Figure 3B-H 
| LBPs reversed the reductions of target proteins of miR-1 and key contractile proteins
In the present study, the repressive effects of miR-1 on the target proteins calmodulin (CaM) and cardiac myosin light chain kinase (cMLCK) are shown in Figure 5A 
| DISCUSSION
MiRNA-based therapy has been recognized to be a promising novel therapeutic strategy for the treatment of cardiovascular diseases. 29, 30 The principal finding of this study is the first to identify Quantitative comparison of QRS and PR interval in all groups. *P < .05, **P < .01 vs WT, # P < .05 vs Tg; mean AE SEM, n = 15 for WT, 9 for Tg, and 7 for LBPs. C, Representative intercalated disc organization showing gap junction and macula adherents detected by TEM. Magnification 925 000, scale bar: 1 lm. D, Quantitative analysis of percentage of damaged length in intercalated disc. **P < .01 vs WT, ## P < .01 vs Tg, data presented as mean AE SEM, n = 3 independent TEM images for each group F I G U R E 3 The mitigating effect of Lycium barbarum polysaccharides (LBPs) on damaged cardiac contractile and diastolic functions by miR-1 overexpression. A-H, Changes of parameters of cardiac systolic and diastolic functions in three groups. *P < .05, **P < .01 vs WT, # P < .05, ## P < .01 vs Tg; mean AE SEM, n = 8 for WT, 6 for Tg, and 6 for LBPs. CO, cardiac output; dP/dt max , maximum derivative of change in systolic pressure over time; dP/dt min , maximum derivative of change in diastolic pressure over time; EDP, end-diastolic pressure; EDV, end-diastolic volume; EF, ejection fraction; ESP, end-systolic pressure; ESV, end-systolic volume F I G U R E 4 The reversing effect of Lycium barbarum polysaccharides (LBPs) on cardiac structural remodelling produced by miR-1 overexpression. A, The change of bodyweight in three groups. *P < .05 vs WT, # P < .05 vs Tg; mean AE SEM, n = 13 for WT, 12 for Tg, and 7 for LBPs. B, The change of ratio of heart to bodyweight in three groups. **P < .01 vs WT; mean AE SEM, n = 13 for WT, 12 for Tg, and 7 for LBPs. C, Longitudinal sections of hearts stained by H&E from mice of three groups, scale bar: 5 mm. D, TEM examination of cardiac myofilament showing sarcomeric length, clear zone and H-zone, and myofibrillar fragmentation and dissolution (in Tg mice). Up panels: magnification 95000, scale bar: 2 lm and down panels: magnification 912 000, scale bar: 2 lm. E, Comparison of length and variation of sarcomeres. **P < .01 vs WT, ## P < .01 vs Tg, data presented as mean AE SD (for variation), n = 80 from three hearts for each group of those patients with many adverse side-effects such as producing poor compliance, promoting myocardial injury and remodelling, deteriorating cardiac function and even increasing the rate of sudden death caused by cardiac arrhythmia. 1, 31 Treatment of HF remains unsatisfactory as available treatments often fail to control the symptoms. 32 Therefore, the current major goal for HF is still to develop rational approaches to improve the quality of life and prolong lifespan. The use of natural compounds to improve human health has long been recognized in the history and increased in popularity in the modern society. The traditional Chinese herb, compared to the Western medicine, has a prominent advantage because of a stable curative effect with significantly less toxicity. With the progression of modern technology, pharmaceutics of herbal medicine products is undergoing rapid development in China, and more and more herbal compound extracts are being authenticated, standardized and administered successfully in clinical practice. 33, 34 Traditional Chinese medicine Tongxinluo (TXL) mediates endothelial preservation by mitigating atherogenesis 35 and improves cardiac functions in response to ischaemia-reperfusion injury. 36 Qili qiangxin capsule, a traditional Chinese medicine, has been approved in China to be used in combination therapy for chronic HF. 34 Of note, several other tra- Lycium barbarum (also known as Goji berry or wolfberry), a famous Chinese medicinal herb and also a functional food, has a long history of use in a broad spectrum of diseases to nourish liver, kidneys and eyes and becomes increasingly popular in Europe and North America. 19, 41, 42 Polysaccharides are the most important functional ingredient that is approximately 40% of dry mass in L. barbarum fruits. 18 Till recent several years LBPs are given increasing attention in the field and most researches focus on its anti-oxidative property as a free radical scavenger for immunomodulation and anticancer. [14] [15] [16] The studies of LBPs on cardiovascular aspect are only limited to the protective phenomena (no discussion of mechanism) on doxorubicin-induced cardiotoxicity and ischaemia/reperfusion injury of rat heart. [21] [22] [23] [24] In the present study, we used the model of cardioprotective role and hope that these novel findings will develop its potential as an evidence-based medicine and expand the application of LBPs on heart disease.
